TERT and central nervous system cancer: As shown in Table 3, TERT promoter mutations (HR = 1.49, 95% CI, 1.05–2.10; P = 0.026) and long RTL (HR = 1.50, 95% CI, 1.04–2.17; P = 0.030) were significantly associated with poor survival in glioma patients.